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Abstract The antitumor agent, paclitaxel (Taxol0), mimics the
actions of lipopolysaccharide (LPS) on murine macrophages
(MP). Various synthetic analogs of paclitaxel were examined for
their potencies to induce nitric oxide (NO) and tumor necrosis
factor (TNF) production by murine peritoneal MP, and by
human peripheral blood cells. The benzoyl group at C-2, the
hydroxy group at C-7 and the acetyl group at C-10 were found to
be critically important sites to activate murine MP. Nor-seco-
taxoid analogs lacking the A ring of the taxane core of paclitaxel
were inactive, but inhibit paclitaxel- or LPS-induced NO
production. All the compounds tested did not induce TNF
production by human blood cells. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Paclitaxel (Taxol0), a complex diterpene isolated from
the stem bark of Taxus brevifolia, has antiproliferative activity
against various cultured cells, antitumor activity in vivo [1^4],
and is currently used as a leading drug for cancer chemother-
apy. The activity is related to its ability to bind L-tubulin, to
promote microtubule assembly, and to stabilize microtubules
by bundle formation [5]. Paclitaxel can mimic certain e¡ects
of bacterial lipopolysaccharide (LPS) on murine peritoneal
macrophages (MP) [6] although it has no chemical structural
similarity to LPS. MP stimulated with LPS produce various
active mediators, including nitric oxide (NO) and tumor ne-
crosis factor (TNF), and they cause endotoxic shock [7,8].
Peritoneal MP derived from LPS-responsive C3H/HeN mice
secrete the mediators when stimulated with paclitaxel or LPS,
whereas the LPS-hyporesponsive C3H/HeJ MP [9,10] cannot
secrete these mediators in response to either LPS or paclitaxel
[6,9^13]. Genetic analysis of recombinant inbred mice re-
vealed a close linkage between the mutant LPSd allele and
the MP inability in response to paclitaxel as well as LPS [6].
These data have provided strong evidence that paclitaxel
shares an intracellular signal transduction pathway with
LPS.
We [14,15] and Burkhart et al. [16] have recently reported
structure^activity relationships of a set of synthetic paclitaxel
analogs (taxoids) for their potencies to induce NO and TNF
production by murine C3H/HeN and C3H/HeJ MP and to
inhibit the growth of MP-like cells. The data indicate that
some parts of the structure in taxoids are related with their
abilities to activate MP, and the presence of an aromatic
group in the N-acylamino group at the C-3P position is the
most important structure to activate C3H/HeN MP [15]. In
addition, we also found that the p-position of the aromatic
group at the C-3P position has a signi¢cant e¡ect on the ac-
tivity [14]. In the present study, synthetic analogs of paclitaxel
modi¢cation at C-2, C-7 and C-10 positions and synthetic
analogs of nor-seco-taxoids lacking the A ring of the taxane
core of paclitaxel were examined for their potencies to induce
NO and TNF production by peritoneal MP of LPS-responsive
C3H/HeN and -hyporesponsive C3H/HeJ mice, and by hu-
man peripheral blood cells.
2. Materials and methods
2.1. Paclitaxel and taxoids
Paclitaxel was obtained from Sigma Chemical Co.; St. Louis, MO,
USA. Taxoids (1^23) and nor-seco-taxoids (24 and 25) were synthe-
sized by means of the L-Lactam Synthon Method [17^20]. The ana-
logs tested and their structures are given in Table 1A,B. Paclitaxel and
taxoids were stored as a 10 mM stock solution in dimethylsulfoxide
(DMSO), and dissolved as reported previously [15].
2.2. Reagents
The Re-chemotype LPS from Salmonella minnesota R595 LPS
was kindly provided by Dr. K. Hisatsune, Josai University, Sakado,
Saitama, Japan. The Ra-chemotype LPS from S. minnesota R60 LPS
was purchased from Sigma Chemical Co., and it was used only in
the experiments using C3H/HeJ MP, because C3H/HeJ MP could
hardly respond to Re-chemotype LPS [21]. Murine recombinant in-
terferon Q (IFNQ) was donated from Shionogi Pharmaceutical Co.,
Osaka, Japan.
2.3. Mice
C3H/HeN and C3H/HeJ mice were bred and maintained in the
Animal Facility of the Jichi Medical School. Female mice were used
at 10^15 weeks of age.
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2.4. MP stimulation
Thioglycolate-elicited murine peritoneal MP, a murine MP-like cell
line, J774.1, and its mutant cell line, J7.DEF.3 [22] were plated in 96-
well plates and stimulated with taxoids or LPS as reported previously
[15]. The J7.DEF.3 cell line is defective in expression of CD14 antigen
[23], a receptor for the complex of LPS and LPS-binding proteins
(reviewed in [8]). In some experiments, MP were preincubated with
taxoids for 2 h, and then stimulated with LPS or paclitaxel. The
culture supernatants were obtained 4 h (for TNF assay) and 48 h
(for NO assay) after the incubation.
2.5. Stimulation of human peripheral blood samples
Fresh heparinized blood samples were obtained from healthy vol-
unteers and were diluted four-fold with serum-free RPMI 1640 me-
dium, plated and then taxoids or LPS were added as described pre-
viously [14]. In some experiments, the diluted samples were incubated
with paclitaxel for 2 h, and then stimulated with 1 ng/ml of LPS. The
culture supernatants were collected for TNF assay.
2.6. TNF and NO assays and detection of inducible NO synthase
(iNOS) in MP
TNF activity was determined by a functional cytotoxic assay using
actinomycin D-treated L929, as described previously [13]. NO forma-
tion was measured as the stable end product nitrite (NO32 ) in culture
supernatants using the Griess reagent [13]. iNOS in the MP was de-
tected by Western blot with anti-iNOS antibody as described previ-
ously [15].
2.7. Cell growth inhibition assay
The growth of J774.1 cells or J7.DEF.3 cells were monitored by a
quantitative calorimetric staining assay using a tetrazolium salt
(MTT) as described previously [15].
3. Results
3.1. NO and TNF production by murine peritoneal MP
stimulated with paclitaxel analogs
Twenty six compounds including paclitaxel (Table 1A,B)
were examined for their ability to induce NO and TNF pro-
duction by the C3H/HeN and C3H/HeJ peritoneal MP, and
the results for C3H/HeN MP are summarized in Table 2. The
dose^responses by C3H/HeN MP to some of the active com-
pounds are shown in Fig. 1A,B. Taxoids 1^3, 6^8, 10^13, 19
and 22^25 with the range of 1^30 WM did not show any ability
to induce NO and TNF production by these MP. Taxoids 5,
18 and 20 induced weak TNF production by C3H/HeN MP,
however, it did not induce any detectable NO production. The
other eight compounds (paclitaxel and taxoids 4, 9, 14^17 and
21) de¢nitely induced both NO and TNF production by C3H/
HeN MP. Among them, paclitaxel and taxoids 9, 16, 17 and
21 showed strong activity in inducing NO and TNF produc-
tion. Especially, taxoid 17 was more active than paclitaxel, i.e.
Table 1A
Chemical structures of paclitaxel and taxoids
Table 1B
Chemical structures of nor-seco-taxoids
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the minimal inducing dose of paclitaxel was 1.9 WM, whereas
that of taxoid 17 was 0.9 WM (Fig. 1). The dose^response
curves for taxoid 17 shifted to about two-fold lower concen-
tration in comparison with those for paclitaxel. The results
suggest that NO and TNF inducibility by these compounds
are fundamentally correlated. LPS-hyporesponsive C3H/HeJ
MP could not produce any detectable NO and TNF in re-
sponse to the active taxoids, even in the presence of IFNQ
(2 U/ml) except for taxoid 5. Taxoid 5 showed a unique ability
to induce TNF production by both C3H/HeN MP (Fig. 1)
and C3H/HeJ MP (Fig. 2) supplemented with IFNQ, albeit
with weak ability. However, taxoid 5 could not induce NO
production at all.
3.2. Structural requirement of active compounds to induce
NO/TNF production by MP
Some special components or groups at the C-2, C-7 and
C-10 positions in taxoids are required for the induction of
NO/TNF production by C3H/HeN MP. The benzoyl group
at the C-2 position is an important structure to induce NO/
TNF production by the MP, i.e. replacement of the benzoyl
group with an acetyl (1), isovaleryl (2), 3-methyl-2-butenoyl
(3), cyclohexanecarbonyl (6), 3-phenylpropionyl (7), or cinna-
moyl (8) group resulted in the substantial loss of activity and
those with 3,3-dimethyl-4-pentenoyl (4) and 3,3-dimethylpen-
tanoyl (5) groups resulted in a diminished activity. A hydroxy
(paclitaxel) or acetyl group (9) at the C-7 position is required
for the induction of NO/TNF, i.e. the introduction of a va-
leryl (10), isovarelyl (11), 3-methyl-2-butenoyl (12), or cinna-
moyl (13) group to this position resulted in loss of the activity.
The substitution of the acetyl group at the C-10 position
especially a¡ected the activity. The introduction of a dodeca-
noyl group (17) to the C-10 position resulted in a distinct gain
of activity. The substitution of a hexanoyl (16) or benzoyl
group (21) virtually did not a¡ect the activity, whereas the
substitution of a propanoyl (14), butanoyl (15), tetradecanoyl
(18), cyclohexanecarbonyl (19), 2-butenoyl (20), dimetylcarba-
moyl (22) or 4-morpholinecarbonyl (23) group resulted in the
decrease or substantial loss of the activity. The A ring of the
taxane core of paclitaxel is an important structure to induce
NO/TNF production by the MP, i.e. nor-seco-taxoids lacking
the A ring of the taxane core (24 and 25) were completely
inactive.
Table 2
Cell-growth inhibition and macrophage activation by taxoids
Compounds Mouse macrophage
activation C3H/HeN
Growth inhibition
(IC50, nM)b
TNF NO J774.1 J7.DEF.3
paclitaxel +++++a ++++ 33 30
1 3 3 s 1000 s 1000
2 3 3 s 1000 s 1000
3 3 3 394 393
4 + + 509 508
5 + 3 508 512
6 3 3 339 448
7 3 3 s 1000 s 1000
8 3 3 s 1000 s 1000
9 +++++ ++++ 39 42
10 3 3 s 1000 s 1000
11 3 3 34 35
12 3 3 44 45
13 3 3 s 1000 s 1000
14 +++ ++ 39 37
15 ++ + 43 36
16 ++++++ ++++ 35 32
17 ++++++ +++++ 622 443
18 + 3 s 1000 s 1000
19 3 3 41 35
20 +++ 3 15 28
21 +++++ +++ 26 32
22 3 3 27 30
23 3 3 41 45
24 3 3 s 1000 s 1000
25 3 3 s 1000 s 1000
aSymbols, ++++++ to ++, indicate the minimal concentration of a
taxoid to induce signi¢cant amounts of NO (s 4 WM) or TNF
(s 20 U/ml); ++++++ 6 0.9 WM, +++++ 6 1.9 WM, ++++ 6 3.8
WM, +++ 6 7.5 WM, ++ 6 15 WM; + indicates the concentration
of a taxoid to induce them was more than 30 WM or 1^4 WM NO
or 10^20 U/ml TNF was induced; 3 indicates that no signi¢cant
NO (6 1 WM) or TNF (6 10 U/ml) was induced. The data on NO
and TNF production were induced from three and two independent
experiments, respectively. Data for paclitaxel are shown for compar-
ison.
bThe concentration of a taxoid which inhibited 50% (IC50) of the
growth of J774.1 cells and J7.DEF.3 cells, after 72 h incubation
with the taxoid. The data represent the mean values of the three in-
dependent experiments. Data for paclitaxel are shown for compari-
son.
Fig. 1. Taxoid-induced NO and TNF production by C3H/HeN MP.
C3H/HeN MP were incubated with various doses of paclitaxel and
taxoids 5 and 17 for 48 h for the NO assay or 4 h for the TNF as-
say. A: NO production was determined by measuring nitrite accu-
mulation in the supernatants in triplicate with Griess reagent. Each
point represents the mean þ standard error of the mean of three or
four experiments. B: TNF activity in the supernatants was deter-
mined by the cytotoxic assay in triplicate using L929 cells. The data
are from one of the two experiments with similar results.
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3.3. TNF production by human peripheral blood cells
stimulated by LPS and paclitaxel analogs
To con¢rm the e¡ect on human cells, we assessed TNF
production by human peripheral blood cell cultures in re-
sponse to LPS and taxoids. As previously reported [13],
LPS induced signi¢cant TNF production by human peripheral
blood cells with optimum response at 18 h, and the response
was dose-dependent with a minimal inducing dose of 0.1 ng/ml.
However, neither taxoids nor nor-seco-taxoids tested with the
range of 1^30 WM did show any ability to induce NO/TNF
production (data not shown).
3.4. E¡ects of pretreatment with taxoids on TNF/NO
production by murine peritoneal MP and human blood cells
in response to paclitaxel or LPS
To determine whether the taxoids modulate the LPS-
or paclitaxel-induced TNF production, C3H/HeN MP and
human blood samples were preincubated with the taxoids
(15 or 30 WM) for 2 h, and then stimulated with 15 WM
paclitaxel or 1 ng/ml LPS. Taxoids 1^3, 6^8, 10^13, 19, 22
and 23, which were inactive to the MP, did not a¡ect or barely
suppressed paclitaxel- or LPS-induced TNF/NO production
(data not shown). The same treatment with inactive nor-
seco-taxoids 24 and 25 did not a¡ect paclitaxel- or LPS-in-
duced TNF production (data not shown), but e¡ectively in-
hibited NO production induced either by paclitaxel or by LPS
in a dose-dependent manner (Fig. 3). Pretreatment of human
blood cells with all 25 compounds tested including nor-seco-
taxoids following paclitaxel- or LPS-stimulation did not in-
duce any detectable TNF production (data not shown).
3.5. E¡ects of pretreatment with nor-seco-taxoid on induction
of iNOS expression in murine peritoneal MP in response to
paclitaxel or LPS
Since the pretreatment of C3H/HeN MP with nor-seco-tax-
oid compound 24 or 25 suppressed paclitaxel- or LPS-induced
NO production, we examined whether or not the suppression
was seen on iNOS expression level. As Fig. 4 shows, the
suppression was indeed seen at the level of iNOS expression.
3.6. Growth inhibitory e¡ect of taxoids on murine MP-like cell
lines
Cell growth inhibitory potencies of the taxoids were exam-
ined against murine MP-like CD14-positive J774.1 cells and
CD14-negative J7.DEF.3 mutant cells, and the results are
summarized in Table 2. Paclitaxel and taxoids 9, 11, 12, 14^
16 and 19^23 inhibited the growth of both cell lines e¡ectively.
Taxoids 3^6 and 17 showed lower activity. Taxoids 1, 2, 7, 8,
10, 13 and 18 as well as nor-seco-taxoids 24 and 25 were
inactive.
3.7. No correlation between the cell growth inhibitory activity
and NO/TNF inducibility
As shown in Table 2, any correlation is hardly seen between
anti-proliferative activities of paclitaxel and taxoids against
murine MP-like J774.1 as well as J7.DEF.3 cells and their
ability to induce NO and TNF production by the C3H/HeN
MP. Paclitaxel and taxoids 9, 16 and 21 showed strong po-
tencies to induce NO/TNF production and to inhibit the cell
growth. On the contrary, taxoids 11, 12, 19, 22 and 23 did not
Fig. 2. LPS- or taxoids-induced TNF production by C3H/HeJ MP.
MP from C3H/HeJ were incubated with 10 ng/ml LPS (open circle)
or taxoid 5 (closed circle) for 4 h. TNF activity in the supernatants
was determined by the cytotoxic assay in triplicate using L929 cells.
The data shown are from one of the three experiments with similar
results.
Fig. 3. E¡ects of pretreatment with nor-seco-taxoids 24 and 25
on LPS- or paclitaxel-induced NO production by C3H/HeN MP.
C3H/HeN MP were preincubated with various doses (indicated on
the abscissa) of 24 (open circle) and 25 (open square) or with
DMSO (closed circle) equivalent to its concentration contained in
these nor-seco-taxoid solutions for 2 h, and then cultured in the
presence of 15 WM paclitaxel (A) or 1 ng/ml LPS (B) for 48 h. NO
production was determined by measuring nitrite accumulation in the
supernatants with Griess reagent in triplicate. Each point represents
the mean standard error of the mean of three or four experiments.
Fig. 4. Nor-seco-taxoids inhibit iNOS production. C3H/He MP were
preincubated with 4, 8 and 15 WM of 24 and 25 or with DMSO
equivalent to its concentration contained in these nor-seco-taxoid
solutions for 2 h, and then stimulated with 15 WM paclitaxel (lower
panel) or 1 ng/ml LPS (upper panel) for 16 h. Expression of iNOS
protein in MP was detected by Western blot analysis with rabbit
anti-iNOS antibody. The iNOS protein expression was quanti¢ed by
Quantity One (Huntington Station, NY, USA). The data are from
one of the four experiments with similar results.
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show any meaningful activity in inducing NO/TNF produc-
tion, but retained the ability to inhibit the cell growth. Where-
as taxoid 17 showed strong potency to induce NO/TNF pro-
duction, it showed no potency to inhibit cell growth. These
¢ndings indicate that the potency of taxoids to induce NO
and TNF production by the murine MP is not correlated to
their growth-inhibitory e¡ect on the murine cells.
4. Discussion
We examined the e¡ects of paclitaxel, its 23 analogs with
modi¢cation of the benzoyl groups at the C-2 position, the
hydroxy group at the C-7 position and the acetyl group at the
C-10 position (R1, R2 and R3 in Table 1A,B, respectively),
and two nor-seco-taxoids on the in vitro inducibility of NO
and TNF production by LPS-responsive C3H/HeN and LPS-
hyporesponsive C3H/HeJ MP as well as NO production by
the human blood cells. None of compounds except taxoid 5
induced the TNF production by C3H/HeJ MP (Fig. 2), even
when the MP were primed with IFNQ. On the other hand,
C3H/HeN MP produced both NO and TNF in response to
some of the taxoids (Table 2), indicating that the LPS-mim-
icking activity, like paclitaxel that can activate C3H/HeN MP
but not C3H/HeJ MP, is retained in these compounds. Also it
is clearly demonstrated that the pretreatment of the MP with
nor-seco-taxoids (24 and 25), which are inactive to induce
TNF and NO production (Table 2), can inhibit NO produc-
tion (Fig. 3) but not TNF production induced by paclitaxel or
LPS (data not shown).
Paclitaxel mimics LPS for its certain e¡ects, including its
inducibility of NO and TNF production by MP of LPS-re-
sponsive mouse strain, but not MP of genetically LPS-hypo-
responsive strain [6,13,24,25]. Some taxoids (4, 9, 14^18, 20
and 21) can also mimic the LPS e¡ects on genetic basis, i.e.
those compounds activate LPS-responsive C3H/HeN MP (Ta-
ble 2), but not LPS-hyporesponsive C3H/HeJ MP. Taxoid 17
which has a dodecanoyl group at the C-10 position among the
taxoids tested shows the strongest ability to induce NO/TNF
production by C3H/HeN MP (Table 2 and Fig. 1). Taxoid 16
with a hexanoyl group at the C-10 position also shows strong
activity. However, taxoids 14 and 15, which have propionyl
and butyryl groups at the same position, respectively, possess
weak activity. Furthermore, taxoid 18 with a tetradecanoyl
group at the same position almost lost activity. These ¢ndings
suggest that the acyl substituent at the C-10 position is very
important for the activity and the length of the acyl chain
seems to determine the strength of the activity. It is well
documented that, in the lipid A portion of LPS, an adequate
length of acyl chain is essential to provoke the endotoxic
activity [8]. Accordingly, it is possible to assume that the
acyl group at the C-10 position of paclitaxel plays a role
similar to that of the acyl group of lipid A.
LPS as well as paclitaxel bind to microtubules [26,27]. Mi-
crotubules are known to associate with many cell functions
such as regulation of TNFK receptor expression on murine
MP [6,28], activation of membrane-bound GTPase [29], asso-
ciation with mitogen-activated protein kinases [30,31], LPS-
induced interleukin-1 production by human monocytes [30]
and LPS and paclitaxel-induced NO synthesis [22]. These
functions of microtubules may be in£uenced by the binding
of LPS or paclitaxel, and presumably of active taxoids. It has
been shown that paclitaxel and its analogs inhibit the cell
growth by stabilizing microtubules [20]. However, microtu-
bules themselves do not seem to act as the common receptors
for LPS and paclitaxel. In fact, our previous study [13] dem-
onstrated that microtubules did not serve as functional recep-
tors for either LPS or paclitaxel to induce TNF and NO
production by murine MP since LPS did not inhibit the bind-
ing and biological action of isotopically labeled paclitaxel to
MP and vice versa. Inhibition of cell growth by paclitaxel is
thought to be due to its binding to microtubules [32]. Among
these active taxoids, no correlation was observed between
TNF/NO production and cell growth inhibition (Table 2).
These ¢ndings may suggest a possibility that the receptors
on MP initiating TNF/NO-induction are di¡erent from those
triggering cell growth inhibition. A recent study demonstrated
that the mutation of C3H/HeJ mice was located in the tlr4
gene coding toll-like receptor (TLR) 4, indicating that TLR 4
was a functional receptor for LPS [33]. TLR 4 may serve as
the receptor of murine MP for paclitaxel as well as its active
analogs. It was reported that in human cells TLR 2 seemed to
be more important than TLR 4 in response to LPS [34]. Pre-
sumably taxoids may not use TLR 2 on human peripheral
blood cells since the cells do not respond to taxoids [14].
It is worth mentioning that taxoid 5, an analog having a
3,3-dimethylpentanoyl group at the C-2 position, is active in
both C3H/HeN and C3H/HeJ MP (Figs. 1B and 2). We re-
cently suggested that LPS from oral black-pigmented bacteria
induces TNF production by C3H/HeJ MP as well as C3H/
HeN MP in a manner di¡erent from that of Salmonella LPS
[21]. Oral black-pigmented bacterial LPS and taxoid 5 may
use other functional receptor(s) di¡erent from TLR 4, such as
other TLR families [35].
In a previous paper [36], we reported that a pretreatment of
C3H/HeN MP with inactive nor-seco-taxoid 25 did not sup-
press subsequent paclitaxel- or LPS-induced TNF production,
but suppressed NO production, indicating that taxoid 25 has
the capability of conditioning MP, albeit that it does not have
ability to induce TNF/NO production. In the present study,
we have found that the majority of non-active taxoids show
little conditioning e¡ect on paclitaxel- or LPS-induced TNF/
NO production. However, the conditioning of C3H/HeN MP
with nor-seco-taxoids 24 and 25 apparently a¡ects the pro-
duction of NO, but not TNF, by a stimulation with either
paclitaxel or LPS (Fig. 3). This result suggests that these com-
pounds are not inactive, but have some priming e¡ect. This
e¡ect can be ascribed to the hindrance of iNOS expression
after the stimulation (Fig. 4). Further study is needed to clar-
ify how the conditioning of murine MP with nor-seco-taxoids
suppresses paclitaxel- or LPS-induced NO production and
why the same pretreatment of human blood cells does not
a¡ect it.
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